Merck & Company (MRK) 54.42 $MRK
Lowest 5-Day Losses on the Dow
Swarup Gupta - Zacks Investment Research - Wed Aug 26, 11:02AM CDT
Over the last five days, the blue-chip index has lost 10.4%.
KO: 38.73 (+0.74), MMM: 142.72 (+5.08), HD: 115.93 (+4.96), MRK: 54.42 (+3.25), XOM: 72.50 (+3.79), DIS: 99.23 (+3.34), WMT: 64.83 (+1.73), CAT: 73.87 (+1.81), CVX: 73.09 (+3.07)
Global Opthalmic Therapeutic Market 2015 Report With Forecasts to 2019
M2 - Wed Aug 26, 10:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kswdmq/global_opthalmic) has announced the addition of the "Global Opthalmic Therapeutic Market 2015-2019" report to their offering. According to the report, the global ophthalmic therapeutic market will grow at a CAGR of 6.53% over the period 2014-2019. The incidence of eye diseases is increasing worldwide, particularly in industrialized and middle-income countries. Changing dietary habits, unhealthy lifestyles, and increased use of electronic equipment such as computers, TVs, and videogames affect normal eyesight. Smoking increases an individual's chances of developing AMD by 2-3 times. Similarly, individuals with diets high in fat, cholesterol, and sugar and low in antioxidants are more likely to be affected by AMD. People with diabetes have a higher risk of being affected by diabetic retinopathy and macular edema. The population of people with diabetes is likely to increase from 382 million in 2013 to 592 million by 2035, leading to a rise in individuals with DME. The total number of cases of diabetic retinopathy is expected to increase from 4.89 million in 2012 to 7.17 million by 2022. The WHO classifies glaucoma as the second leading cause of visual impairment in the world, affecting about 285 million people worldwide. Further, the report states that the limited public awareness of eye diseases restricts the market growth. Key Topics Covered - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Disease Overview - Pipeline Analysis - Market Landscape - Market Segmentation by Disease Type - Market Segmentation by Route of Administration - Market Segmentation by Molecule Type - Market Segmentation by Dosage Form - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and Their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and Their Impact - Vendor Landscape - Key Vendor Analysis Companies Mentioned Partial list of the 60 companies featured in this comprehensive report: - Acadia Pharmaceuticals - Actavis - Bayer - BCN Peptides - Carl Zeiss Meditec - Eleven Biotherapeutics - F. Hoffmann-La Roche - Falcon Pharmaceuticals - Gilead Sciences - GlaxoSmithKline - Icon Bioscience - Lexicon Pharmaceuticals - Merck - Novartis - Ohr Pharmaceutical - PanOptica - Pfizer - Quark Pharmaceuticals - Regeneron Pharmaceuticals - Seikagaku - StemCells - ThromboGenics - Valeant Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/ks..._opthalmic
ACAD: 36.38 (+2.24), LXRX: 12.07 (+0.05), GILD: 106.96 (+4.40), MRK: 54.42 (+3.25), OHRP: 2.63 (+0.15), GSK: 40.47 (+1.06), REGN: 535.47 (+36.45), NVS: 97.13 (+1.99)
Stocks Open Higher In Weak Trade; Netflix, Google, Amazon Rocket
at Investor's Business Daily - Wed Aug 26, 9:25AM CDT
Stocks charged higher at the starting bell for a second straight day on Wednesday. Volume was soft across the board as the Dow Jones industrial average and the S&P 500 notched 2.3% gains. The Nasdaq was up 2.4%. All had pulled back from their opening...
AMZN: 500.77 (+34.40), CAM: 59.93 (+17.46), WETF: 17.93 (-0.64), WYNN: 74.29 (-1.42), SLB: 70.09 (-2.43), NFLX: 110.13 (+8.61), V: 70.69 (+3.72), JPM: 62.91 (+3.00), MRK: 54.42 (+3.25), SCMP: 24.55 (+0.61), GOOGL: 659.74 (+47.27), AAPL: 109.69 (+5.95)
Hepatitis C Market & Forecast, Hepatitis C Pipeline Drugs Sales & Forecast, Clinical Trials - Global
M2 - Wed Aug 26, 8:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mwjwh6/hepatitis_c) has announced the addition of the "Hepatitis C Market & Forecast, Hepatitis C Pipeline Drugs Sales & Forecast, Clinical Trials - Global" report to their offering. Market for Hepatitis C drugs has grown with a phenomenal rate of more than US$ 13 Billion, in the year 2014 compared to 2013. In the last two years a couple of new drugs have been introduced in the market which has become a huge success and they have captured maximum market share of the Hepatitis C market. Gilead currently dominates the multi-billion dollar Hepatitis C market, but AbbVie has been trying to increase its market share since U.S. regulators approved the marketing of its Viekira Pak. Drug makers are already focusing on introducing new drugs in the market as several drugs are standing in the pipeline. Hepatitis C Drugs is anticipated to be a rosy market for future period. Key Topics Covered - Executive Summary - Hepatitis C Drugs - Market & Forecast - Hepatitis C - Approved Drugs Sales & Forecast - Hepatitis C - Pipeline Drugs Sales Forecast - Hepatitis C - Deals & Acquisitions - Hepatitis C - Company Wise Clinical Trials Analysis Companies Mentioned - AbbVie - Bristol-Myers Squibb (BMS) - Gilead Sciences - Merck & Co. - Tibotec/Janssen Therapeutics For more information visit http://www.researchandmarkets.com/research/mw...epatitis_c
GILD: 106.96 (+4.40), MRK: 54.42 (+3.25), BMY: 60.03 (+2.15)
PAREXEL Names Maykin Ho to Board of Directors
PR Newswire - Wed Aug 26, 8:00AM CDT
PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that its Board of Directors have elected Maykin Ho, Ph.D., to the Board, effective August 26, 2015.
PRXL: 67.99 (+1.21), MRK: 54.42 (+3.25)
The Snap-Back Rally Snapped Yesterday, But There’s Hope Today – Markets This Morning
Dana Blankenhorn - Amigobulls - Wed Aug 26, 4:07AM CDT
China & Japan saw their stock markets bounce back, implying that we might finally see some relief in other markets today - Markets This Morning
NFLX: 110.13 (+8.61), AMZN: 500.77 (+34.40), GE: 24.01 (+0.74), UTX: 91.56 (+2.76), MRK: 54.42 (+3.25), GOOGL: 659.74 (+47.27), MSFT: 42.71 (+2.24), GOOG: 628.62 (+46.56), AAPL: 109.69 (+5.95)
Merck Falls 3.19% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Mon Aug 24, 5:17PM CDT
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $45.69 to a high of $55.13. Yesterday, the shares fell 3.2%, which took the trading range below the 3-day low of $55.76 on volume of 24.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MRK: 54.42 (+3.25)
After Yesterday's Decline of 3.19%, Merck Offers Investors Better Value
Comtex SmarTrend(R) - Mon Aug 24, 5:16PM CDT
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $45.69 to a high of $55.13. Yesterday, the shares fell 3.2%, which took the trading range below the 3-day low of $55.76 on volume of 24.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MRK: 54.42 (+3.25)
Merck (MRK) Breaks Through Support at $55.14
Comtex SmarTrend(R) - Mon Aug 24, 12:33PM CDT
Shares of Merck (NYSE:MRK) opened today below their pivot of $56.39 and have already reached the first level of support at $55.14. Investors may be interested in a cross of the next downside pivot targets of $54.52 and $52.65.
MRK: 54.42 (+3.25)
Northwest Bio Forced to Temporarily Halt Study of Brain Tumor Vaccine
at The Street - Mon Aug 24, 7:53AM CDT
Enrollment of new patients into the DCVax-L study is suspended until the company "submits certain information from the trial for regulatory review," Northwest Bio said.
NWBO: 7.87 (+0.18), MRK: 54.42 (+3.25), CLDX: 14.36 (+0.39), BMY: 60.03 (+2.15)
From Cancer To Ebola, NewLink Genetics Seeks Vaccines
at Investor's Business Daily - Fri Aug 21, 5:18PM CDT
As an undergrad, Chuck Link studied at the U.S. Air Force Academy. Then he attended Stanford University and graduated from its medical school as a newly minted M.D. Link, 55, is now chairman, chief executive and chief scientific officer of NewLink...
MRK: 54.42 (+3.25), NLNK: 46.45 (+1.30)
Stocks Hit New Session Lows; Ambarella, Netflix Hit Hard
at Investor's Business Daily - Fri Aug 21, 10:52AM CDT
Earlier comeback efforts collapsed, sending stocks to fresh session lows near midday Friday. Continuing concerns over global growth are again weighing on the stock market today. The Nasdaq tumbled 2% and the S&P 500 lost 1.7%. Both hit six-month...
NFLX: 110.13 (+8.61), AMBA: 89.46 (+2.46), MENT: 24.96 (+0.81), SKX: 137.29 (+5.33), MRK: 54.42 (+3.25)
Dow 30 Stock Roundup: Walmart Misses on Earnings, GS Bank to Buy GE Capital Bank's Online Platform
A Clark - Zacks Investment Research - Fri Aug 21, 10:05AM CDT
The Dow suffered a particularly dismal week due to multiple concerns.
KO: 38.73 (+0.74), GE: 24.01 (+0.74), HD: 115.93 (+4.96), GS: 184.40 (+6.18), V: 70.69 (+3.72), JPM: 62.91 (+3.00), MRK: 54.42 (+3.25), XOM: 72.50 (+3.79), DIS: 99.23 (+3.34), WMT: 64.83 (+1.73), CVX: 73.09 (+3.07)
Stock Market News for August 21, 2015
Zacks Equity Research - Zacks Investment Research - Fri Aug 21, 9:10AM CDT
Benchmarks slumped to multi-month lows on Thursday on concerns that a weak Chinese economy would result in a global slowdown
DHI: 29.52 (+1.24), KO: 38.73 (+0.74), MDLZ: 42.20 (+0.89), DIS: 99.23 (+3.34), WMT: 64.83 (+1.73), PEP: 92.49 (+2.85), PM: 79.75 (+2.36), LEN: 49.70 (+1.52), WBA: 85.41 (+4.41), MRK: 54.42 (+3.25), PHM: 19.82 (+0.91), COST: 138.16 (+5.45), OC: 43.59 (+0.88), PG: 70.90 (+2.48), AAPL: 109.69 (+5.95), CL: 62.23 (+1.86)
Biotech Stock Mailbag: Celldex, Bluebird, Kite, Inovio
at The Street - Fri Aug 21, 4:55AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
BLUE: 129.67 (+4.60), INO: 6.80 (+0.21), GBT: 40.76 (-2.11), KITE: 51.53 (+1.49), PFE: 32.43 (+1.09), MRK: 54.42 (+3.25), CLDX: 14.36 (+0.39), AZN: 31.13 (+0.85), JUNO: 36.50 (+0.69)
New Skin Cancer Drugs Delayed (but Investors and Patients Needn't Worry)
Brian Orelli, The Motley Fool - Motley Fool - Thu Aug 20, 7:40PM CDT
During the last week or so, both Bristol-Myers Squibb and Merck have announced delays in Food and Drug Administration decisions on approvals for their immuno-oncology drugs to treat melanoma. A decision on whether to expand the approval of...
MRK: 54.42 (+3.25), BMY: 60.03 (+2.15)
Diabetes drug shows 1st protection from heart complications
By LINDA A. JOHNSON - AP - Thu Aug 20, 4:03PM CDT
TRENTON, N.J. (AP) — For the first time, there's evidence that a diabetes medication, Jardiance, reduces risk of the complications that are the top killer of diabetics: heart attacks, strokes and other cardiovascular damage.
MRK: 54.42 (+3.25), LLY: 81.10 (+2.84)
These 2 Dividend Leaders Hold Up Well In Rocky Market
at Investor's Business Daily - Thu Aug 20, 4:01PM CDT
Stocks with high dividend yields aren't hard to find in the utility and REIT space. Problem is, very few stocks are showing relative strength. But it's a different story for a couple of Dividend Leaders. Dow componentsPfizer (PFE) and Merck (MRK) are...
LMT: 202.12 (+3.14), MRK: 54.42 (+3.25), PFE: 32.43 (+1.09)
Watch for Merck to Potentially Rebound After Falling 4.51% Yesterday
Comtex SmarTrend(R) - Thu Aug 20, 3:50PM CDT
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $56.74 to a high of $58.55. Yesterday, the shares fell 4.5%, which took the trading range below the 3-day low of $58.58 on volume of 22.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MRK: 54.42 (+3.25)
Lowest 5-Day Losses on the Dow
Swarup Gupta - Zacks Investment Research - Wed Aug 26, 11:02AM CDT
Over the last five days, the blue-chip index has lost 10.4%.
KO: 38.73 (+0.74), MMM: 142.72 (+5.08), HD: 115.93 (+4.96), MRK: 54.42 (+3.25), XOM: 72.50 (+3.79), DIS: 99.23 (+3.34), WMT: 64.83 (+1.73), CAT: 73.87 (+1.81), CVX: 73.09 (+3.07)
Global Opthalmic Therapeutic Market 2015 Report With Forecasts to 2019
M2 - Wed Aug 26, 10:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kswdmq/global_opthalmic) has announced the addition of the "Global Opthalmic Therapeutic Market 2015-2019" report to their offering. According to the report, the global ophthalmic therapeutic market will grow at a CAGR of 6.53% over the period 2014-2019. The incidence of eye diseases is increasing worldwide, particularly in industrialized and middle-income countries. Changing dietary habits, unhealthy lifestyles, and increased use of electronic equipment such as computers, TVs, and videogames affect normal eyesight. Smoking increases an individual's chances of developing AMD by 2-3 times. Similarly, individuals with diets high in fat, cholesterol, and sugar and low in antioxidants are more likely to be affected by AMD. People with diabetes have a higher risk of being affected by diabetic retinopathy and macular edema. The population of people with diabetes is likely to increase from 382 million in 2013 to 592 million by 2035, leading to a rise in individuals with DME. The total number of cases of diabetic retinopathy is expected to increase from 4.89 million in 2012 to 7.17 million by 2022. The WHO classifies glaucoma as the second leading cause of visual impairment in the world, affecting about 285 million people worldwide. Further, the report states that the limited public awareness of eye diseases restricts the market growth. Key Topics Covered - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Disease Overview - Pipeline Analysis - Market Landscape - Market Segmentation by Disease Type - Market Segmentation by Route of Administration - Market Segmentation by Molecule Type - Market Segmentation by Dosage Form - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and Their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and Their Impact - Vendor Landscape - Key Vendor Analysis Companies Mentioned Partial list of the 60 companies featured in this comprehensive report: - Acadia Pharmaceuticals - Actavis - Bayer - BCN Peptides - Carl Zeiss Meditec - Eleven Biotherapeutics - F. Hoffmann-La Roche - Falcon Pharmaceuticals - Gilead Sciences - GlaxoSmithKline - Icon Bioscience - Lexicon Pharmaceuticals - Merck - Novartis - Ohr Pharmaceutical - PanOptica - Pfizer - Quark Pharmaceuticals - Regeneron Pharmaceuticals - Seikagaku - StemCells - ThromboGenics - Valeant Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/ks..._opthalmic
ACAD: 36.38 (+2.24), LXRX: 12.07 (+0.05), GILD: 106.96 (+4.40), MRK: 54.42 (+3.25), OHRP: 2.63 (+0.15), GSK: 40.47 (+1.06), REGN: 535.47 (+36.45), NVS: 97.13 (+1.99)
Stocks Open Higher In Weak Trade; Netflix, Google, Amazon Rocket
at Investor's Business Daily - Wed Aug 26, 9:25AM CDT
Stocks charged higher at the starting bell for a second straight day on Wednesday. Volume was soft across the board as the Dow Jones industrial average and the S&P 500 notched 2.3% gains. The Nasdaq was up 2.4%. All had pulled back from their opening...
AMZN: 500.77 (+34.40), CAM: 59.93 (+17.46), WETF: 17.93 (-0.64), WYNN: 74.29 (-1.42), SLB: 70.09 (-2.43), NFLX: 110.13 (+8.61), V: 70.69 (+3.72), JPM: 62.91 (+3.00), MRK: 54.42 (+3.25), SCMP: 24.55 (+0.61), GOOGL: 659.74 (+47.27), AAPL: 109.69 (+5.95)
Hepatitis C Market & Forecast, Hepatitis C Pipeline Drugs Sales & Forecast, Clinical Trials - Global
M2 - Wed Aug 26, 8:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mwjwh6/hepatitis_c) has announced the addition of the "Hepatitis C Market & Forecast, Hepatitis C Pipeline Drugs Sales & Forecast, Clinical Trials - Global" report to their offering. Market for Hepatitis C drugs has grown with a phenomenal rate of more than US$ 13 Billion, in the year 2014 compared to 2013. In the last two years a couple of new drugs have been introduced in the market which has become a huge success and they have captured maximum market share of the Hepatitis C market. Gilead currently dominates the multi-billion dollar Hepatitis C market, but AbbVie has been trying to increase its market share since U.S. regulators approved the marketing of its Viekira Pak. Drug makers are already focusing on introducing new drugs in the market as several drugs are standing in the pipeline. Hepatitis C Drugs is anticipated to be a rosy market for future period. Key Topics Covered - Executive Summary - Hepatitis C Drugs - Market & Forecast - Hepatitis C - Approved Drugs Sales & Forecast - Hepatitis C - Pipeline Drugs Sales Forecast - Hepatitis C - Deals & Acquisitions - Hepatitis C - Company Wise Clinical Trials Analysis Companies Mentioned - AbbVie - Bristol-Myers Squibb (BMS) - Gilead Sciences - Merck & Co. - Tibotec/Janssen Therapeutics For more information visit http://www.researchandmarkets.com/research/mw...epatitis_c
GILD: 106.96 (+4.40), MRK: 54.42 (+3.25), BMY: 60.03 (+2.15)
PAREXEL Names Maykin Ho to Board of Directors
PR Newswire - Wed Aug 26, 8:00AM CDT
PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that its Board of Directors have elected Maykin Ho, Ph.D., to the Board, effective August 26, 2015.
PRXL: 67.99 (+1.21), MRK: 54.42 (+3.25)
The Snap-Back Rally Snapped Yesterday, But There’s Hope Today – Markets This Morning
Dana Blankenhorn - Amigobulls - Wed Aug 26, 4:07AM CDT
China & Japan saw their stock markets bounce back, implying that we might finally see some relief in other markets today - Markets This Morning
NFLX: 110.13 (+8.61), AMZN: 500.77 (+34.40), GE: 24.01 (+0.74), UTX: 91.56 (+2.76), MRK: 54.42 (+3.25), GOOGL: 659.74 (+47.27), MSFT: 42.71 (+2.24), GOOG: 628.62 (+46.56), AAPL: 109.69 (+5.95)
Merck Falls 3.19% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Mon Aug 24, 5:17PM CDT
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $45.69 to a high of $55.13. Yesterday, the shares fell 3.2%, which took the trading range below the 3-day low of $55.76 on volume of 24.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MRK: 54.42 (+3.25)
After Yesterday's Decline of 3.19%, Merck Offers Investors Better Value
Comtex SmarTrend(R) - Mon Aug 24, 5:16PM CDT
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $45.69 to a high of $55.13. Yesterday, the shares fell 3.2%, which took the trading range below the 3-day low of $55.76 on volume of 24.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MRK: 54.42 (+3.25)
Merck (MRK) Breaks Through Support at $55.14
Comtex SmarTrend(R) - Mon Aug 24, 12:33PM CDT
Shares of Merck (NYSE:MRK) opened today below their pivot of $56.39 and have already reached the first level of support at $55.14. Investors may be interested in a cross of the next downside pivot targets of $54.52 and $52.65.
MRK: 54.42 (+3.25)
Northwest Bio Forced to Temporarily Halt Study of Brain Tumor Vaccine
at The Street - Mon Aug 24, 7:53AM CDT
Enrollment of new patients into the DCVax-L study is suspended until the company "submits certain information from the trial for regulatory review," Northwest Bio said.
NWBO: 7.87 (+0.18), MRK: 54.42 (+3.25), CLDX: 14.36 (+0.39), BMY: 60.03 (+2.15)
From Cancer To Ebola, NewLink Genetics Seeks Vaccines
at Investor's Business Daily - Fri Aug 21, 5:18PM CDT
As an undergrad, Chuck Link studied at the U.S. Air Force Academy. Then he attended Stanford University and graduated from its medical school as a newly minted M.D. Link, 55, is now chairman, chief executive and chief scientific officer of NewLink...
MRK: 54.42 (+3.25), NLNK: 46.45 (+1.30)
Stocks Hit New Session Lows; Ambarella, Netflix Hit Hard
at Investor's Business Daily - Fri Aug 21, 10:52AM CDT
Earlier comeback efforts collapsed, sending stocks to fresh session lows near midday Friday. Continuing concerns over global growth are again weighing on the stock market today. The Nasdaq tumbled 2% and the S&P 500 lost 1.7%. Both hit six-month...
NFLX: 110.13 (+8.61), AMBA: 89.46 (+2.46), MENT: 24.96 (+0.81), SKX: 137.29 (+5.33), MRK: 54.42 (+3.25)
Dow 30 Stock Roundup: Walmart Misses on Earnings, GS Bank to Buy GE Capital Bank's Online Platform
A Clark - Zacks Investment Research - Fri Aug 21, 10:05AM CDT
The Dow suffered a particularly dismal week due to multiple concerns.
KO: 38.73 (+0.74), GE: 24.01 (+0.74), HD: 115.93 (+4.96), GS: 184.40 (+6.18), V: 70.69 (+3.72), JPM: 62.91 (+3.00), MRK: 54.42 (+3.25), XOM: 72.50 (+3.79), DIS: 99.23 (+3.34), WMT: 64.83 (+1.73), CVX: 73.09 (+3.07)
Stock Market News for August 21, 2015
Zacks Equity Research - Zacks Investment Research - Fri Aug 21, 9:10AM CDT
Benchmarks slumped to multi-month lows on Thursday on concerns that a weak Chinese economy would result in a global slowdown
DHI: 29.52 (+1.24), KO: 38.73 (+0.74), MDLZ: 42.20 (+0.89), DIS: 99.23 (+3.34), WMT: 64.83 (+1.73), PEP: 92.49 (+2.85), PM: 79.75 (+2.36), LEN: 49.70 (+1.52), WBA: 85.41 (+4.41), MRK: 54.42 (+3.25), PHM: 19.82 (+0.91), COST: 138.16 (+5.45), OC: 43.59 (+0.88), PG: 70.90 (+2.48), AAPL: 109.69 (+5.95), CL: 62.23 (+1.86)
Biotech Stock Mailbag: Celldex, Bluebird, Kite, Inovio
at The Street - Fri Aug 21, 4:55AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
BLUE: 129.67 (+4.60), INO: 6.80 (+0.21), GBT: 40.76 (-2.11), KITE: 51.53 (+1.49), PFE: 32.43 (+1.09), MRK: 54.42 (+3.25), CLDX: 14.36 (+0.39), AZN: 31.13 (+0.85), JUNO: 36.50 (+0.69)
New Skin Cancer Drugs Delayed (but Investors and Patients Needn't Worry)
Brian Orelli, The Motley Fool - Motley Fool - Thu Aug 20, 7:40PM CDT
During the last week or so, both Bristol-Myers Squibb and Merck have announced delays in Food and Drug Administration decisions on approvals for their immuno-oncology drugs to treat melanoma. A decision on whether to expand the approval of...
MRK: 54.42 (+3.25), BMY: 60.03 (+2.15)
Diabetes drug shows 1st protection from heart complications
By LINDA A. JOHNSON - AP - Thu Aug 20, 4:03PM CDT
TRENTON, N.J. (AP) — For the first time, there's evidence that a diabetes medication, Jardiance, reduces risk of the complications that are the top killer of diabetics: heart attacks, strokes and other cardiovascular damage.
MRK: 54.42 (+3.25), LLY: 81.10 (+2.84)
These 2 Dividend Leaders Hold Up Well In Rocky Market
at Investor's Business Daily - Thu Aug 20, 4:01PM CDT
Stocks with high dividend yields aren't hard to find in the utility and REIT space. Problem is, very few stocks are showing relative strength. But it's a different story for a couple of Dividend Leaders. Dow componentsPfizer (PFE) and Merck (MRK) are...
LMT: 202.12 (+3.14), MRK: 54.42 (+3.25), PFE: 32.43 (+1.09)
Watch for Merck to Potentially Rebound After Falling 4.51% Yesterday
Comtex SmarTrend(R) - Thu Aug 20, 3:50PM CDT
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $56.74 to a high of $58.55. Yesterday, the shares fell 4.5%, which took the trading range below the 3-day low of $58.58 on volume of 22.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MRK: 54.42 (+3.25)
